{"title":"Clinical Application of Cell Therapy in the Treatment of Female Reproductive Diseases: A Systematic Review.","authors":"Fatemeh Saberi, Zeinab Dehghan, Shayesteh Mehdinejadiani, Zahra Khosravizadeh, Effat Noori, Tayyebeh Pilehchi, Delsuz Rezaee, Zahra Taheri, Azam Govahi, Nasim Goudarzi, Kobra Mehdinejadiani, Forough Shams","doi":"10.1177/21524971251379699","DOIUrl":null,"url":null,"abstract":"<p><p>Reproductive disorders affect millions of women worldwide, playing a crucial role in determining female fertility health and quality of life. Conventional methods such as surgery, hormone therapy, and assisted reproductive technologies can be successful in some cases, but are limited by adverse effects, and limited effectiveness. In recent years, cell therapy has provided new possibilities for treating various infertility disorders. The articles extracted from PubMed and Scopus databases were based on cell therapy premature ovarian failure (POF), intrauterine adhesions, Asherman syndrome (AS), recurrent implantation failure (RIF), repeat implantation failure, polycystic ovary syndrome (PCOS), endometriosis, preeclampsia, and clinical trials. The collected articles were added to EndNote X7, and review articles along with duplicate studies were eliminated. Several studies have indicated that peripheral blood mononuclear cells, autologous platelet-rich plasma, mesenchymal stem cells (MSCs), hematopoietic stem cells (HSCs), adipose-derived stromal vascular fraction, and umbilical cord stem cells can be used to treat reproductive diseases, including POF, AS, and RIF. PCOS, endometriosis, and preeclampsia were deleted from the study, because there were no clinical cell therapy studies for these diseases. Among the 210 studies, 28 were selected as eligible for further evaluation. Various clinical trials have supported the role of cell therapy in treating reproductive disorders. Although the information from this systematic review is promising, further studies are needed to evaluate the efficacy and safety of these and other cells in treating infertility.</p>","PeriodicalId":9708,"journal":{"name":"Cellular reprogramming","volume":" ","pages":"184-198"},"PeriodicalIF":1.7000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cellular reprogramming","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/21524971251379699","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/23 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Reproductive disorders affect millions of women worldwide, playing a crucial role in determining female fertility health and quality of life. Conventional methods such as surgery, hormone therapy, and assisted reproductive technologies can be successful in some cases, but are limited by adverse effects, and limited effectiveness. In recent years, cell therapy has provided new possibilities for treating various infertility disorders. The articles extracted from PubMed and Scopus databases were based on cell therapy premature ovarian failure (POF), intrauterine adhesions, Asherman syndrome (AS), recurrent implantation failure (RIF), repeat implantation failure, polycystic ovary syndrome (PCOS), endometriosis, preeclampsia, and clinical trials. The collected articles were added to EndNote X7, and review articles along with duplicate studies were eliminated. Several studies have indicated that peripheral blood mononuclear cells, autologous platelet-rich plasma, mesenchymal stem cells (MSCs), hematopoietic stem cells (HSCs), adipose-derived stromal vascular fraction, and umbilical cord stem cells can be used to treat reproductive diseases, including POF, AS, and RIF. PCOS, endometriosis, and preeclampsia were deleted from the study, because there were no clinical cell therapy studies for these diseases. Among the 210 studies, 28 were selected as eligible for further evaluation. Various clinical trials have supported the role of cell therapy in treating reproductive disorders. Although the information from this systematic review is promising, further studies are needed to evaluate the efficacy and safety of these and other cells in treating infertility.
期刊介绍:
Cellular Reprogramming is the premier journal dedicated to providing new insights on the etiology, development, and potential treatment of various diseases through reprogramming cellular mechanisms. The Journal delivers information on cutting-edge techniques and the latest high-quality research and discoveries that are transforming biomedical research.
Cellular Reprogramming coverage includes:
Somatic cell nuclear transfer and reprogramming in early embryos
Embryonic stem cells
Nuclear transfer stem cells (stem cells derived from nuclear transfer embryos)
Generation of induced pluripotent stem (iPS) cells and/or potential for cell-based therapies
Epigenetics
Adult stem cells and pluripotency.